WP
LRMR icon

Woodline Partners’s Larimar Therapeutics LRMR Stock Holding History

Woodline Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.3M Buy
1,400,850
+600,000
+75% +$2.4M 0.02% 615
2025
Q4 		$3.05M Sell
800,850
-822,000
-51% -$3.2M 0.01% 715
2025
Q3 		$5.24M Buy
1,622,850
+1,000,168
+161% +$3.75M 0.02% 557
2025
Q2 		$1.8M Hold
622,682
– – 0.01% 737
2025
Q1 		$1.34M Hold
622,682
– – 0.01% 728
2024
Q4 		$2.41M Sell
622,682
-621,869
-50% -$4.11M 0.02% 624
2024
Q3 		$8.15M Buy
1,244,551
+1,966
+0.2% +$15.8K 0.07% 331
2024
Q2 		$9.01M Buy
1,242,585
+92,252
+8% +$707K 0.09% 262
2024
Q1 		$8.73M Buy
1,150,333
+354,107
+44% +$2.76M 0.08% 289
2023
Q4 		$3.62M Buy
796,226
+86,545
+12% +$292K 0.04% 344
2023
Q3 		$2.8M Sell
709,681
-972,232
-58% -$3.68M 0.03% 370
2023
Q2 		$5.26M Hold
1,681,913
– – 0.06% 280
2023
Q1 		$7.62M Sell
1,681,913
-259,826
-13% -$1.36M 0.1% 237
2022
Q4 		$8.02M Hold
1,941,739
– – 0.11% 245
2022
Q3 		$6.21M Buy
+1,941,739
New +$4.86M 0.09% 260

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Woodline Partners's LRMR Position: Q1 2026 in Review

Woodline Partners increased its Larimar Therapeutics (LRMR) stake by 75% in Q1 2026, buying an estimated $2.4M and bringing the position to 1,400,850 shares worth $6.3M. The position accounts for 0.02% of the portfolio, ranked #615.

Woodline Partners first reported a position in LRMR in Q3 2022 and has held it in 15 quarters since. The position peaked at $9.01M in Q2 2024. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Woodline Partners held 1,400,850 shares of Larimar Therapeutics worth $6.3M as of Q1 2026.
  • Woodline Partners bought 600,000 Larimar Therapeutics shares in Q1 2026, an estimated $2.4M.
  • Larimar Therapeutics made up 0.02% of Woodline Partners's portfolio in Q1 2026, its #615 holding.
  • Woodline Partners first reported a position in Larimar Therapeutics in Q3 2022 and has held it in 15 quarters since.
  • Woodline Partners's Larimar Therapeutics position peaked at $9.01M in Q2 2024.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.